Study drug for people with advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign a consent form and agree to follow the study rules.
- You’re between 18 and 75 years old (any sex).
- You have advanced solid cancer that has already failed standard treatment, with no effective option right now.
- If you could become pregnant (or have a partner who could), you must use reliable birth control during the study and for at least 90 days after the dose; pregnancy test is required for people who can become pregnant.
- You should not have had another unlisted research drug within 4 weeks before starting this study.
- You should not have recent major surgery or major injury in the 4 weeks before the first dose, and you should not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, VG2025, given through a vein for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the tumors.
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
This trial tests a new treatment that uses a virus to attack tumor cells directly. It is for people with advanced pancreatic cancer that has not responded to standard therapy. The virus is injected into a tumor, and the goal is to see if it can shrink the cancer or slow its growth.
This trial tests a new drug called VG2025 to treat advanced intrahepatic cholangiocarcinoma, a type of cancer that starts in the bile ducts inside the liver. The study aims to see if VG2025 is safe and effective at slowing or stopping this cancer.
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
Hear when a new Advanced Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.